RAM
IOVA icon

Roanoke Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Roanoke Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$134K Hold
40,360
– – 0.05% 88
2024
Q4 		$299K Hold
40,360
– – 0.1% 74
2024
Q3 		$379K Hold
40,360
– – 0.12% 75
2024
Q2 		$324K Hold
40,360
– – 0.11% 75
2024
Q1 		$598K Sell
40,360
-780
-2% -$9.08K 0.2% 62
2023
Q4 		$334K Buy
41,140
+5,840
+17% +$30.6K 0.12% 78
2023
Q3 		$161K Hold
35,300
– – 0.07% 93
2023
Q2 		$249K Buy
35,300
+22,500
+176% +$161K 0.1% 93
2023
Q1 		$78K Buy
+12,800
New +$88.3K 0.03% 100

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Roanoke Asset Management's IOVA Position: Q1 2025 in Review

Roanoke Asset Management held its Iovance Biotherapeutics (IOVA) position steady in Q1 2025 at 40,360 shares worth $134K. The position accounts for 0.05% of the portfolio, ranked #88.

Roanoke Asset Management first reported a position in IOVA in Q1 2023 and has held it in 9 quarters since. The position peaked at $598K in Q1 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Roanoke Asset Management held 40,360 shares of Iovance Biotherapeutics worth $134K as of Q1 2025.
  • Roanoke Asset Management left its Iovance Biotherapeutics share count unchanged in Q1 2025.
  • Iovance Biotherapeutics made up 0.05% of Roanoke Asset Management's portfolio in Q1 2025, its #88 holding.
  • Roanoke Asset Management first reported a position in Iovance Biotherapeutics in Q1 2023 and has held it in 9 quarters since.
  • Roanoke Asset Management's Iovance Biotherapeutics position peaked at $598K in Q1 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Roanoke Asset Management's 13F filing for Q1 2025, filed 13 May 2025.